Takeda Pharma Files 6-K for June 2025

Ticker: TKPHF · Form: 6-K · Filed: Jun 25, 2025 · CIK: 1395064

Takeda Pharmaceutical Co Ltd 6-K Filing Summary
FieldDetail
CompanyTakeda Pharmaceutical Co Ltd (TKPHF)
Form Type6-K
Filed DateJun 25, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: foreign-private-issuer, sec-filing, routine-update

TL;DR

Takeda filed its June 6-K, confirming 20-F annual reports and Tokyo HQ.

AI Summary

Takeda Pharmaceutical Company Limited filed a Form 6-K on June 25, 2025, reporting as a foreign private issuer. The filing is for the month of June 2025 and indicates Takeda will file its annual reports under Form 20-F. The company's principal executive offices are located in Tokyo, Japan.

Why It Matters

This filing provides routine updates for Takeda as a foreign private issuer, confirming its reporting status and principal office location.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no new financial or operational information that would indicate increased risk.

Key Players & Entities

  • Takeda Pharmaceutical Company Limited (company) — Registrant
  • Tokyo, Japan (location) — Principal executive offices

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, providing information that the registrant makes or is required to make public in its home country, files or is required to file with a stock exchange, or distributes or is required to distribute to its security holders.

Which form does Takeda use for its annual reports?

Takeda Pharmaceutical Company Limited indicates it files its annual reports under cover of Form 20-F.

Where are Takeda's principal executive offices located?

Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan.

What is the filing date of this Form 6-K?

This Form 6-K was filed on June 25, 2025.

Is Takeda submitting this Form 6-K in paper format?

The filing indicates that Takeda is not submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) or Rule 101(b)(7).

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on June 25, 2025 regarding TAKEDA PHARMACEUTICAL CO LTD (TKPHF).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.